Background/Aims Acetyl coenzyme A (acetyl-CoA) is one of the most essential metabolites in cell metabolism but its function and concentration in hepatocellular carcinoma (HCC) remain elusive and controversial.
Methods A comprehensive analysis of acetyl-CoA levels and acetyl-CoA synthetase 2 (ACSS2) expression across a range of samples, including patient specimens from both hepatitis B virus (HBV) positive and HBV negative HCC individuals, HBV-transgenic mouse HCC models, and multiple cell lines. Furthermore, to evaluate the functional significance of ACSS2 in HBV-related HCC, we implemented both genetic and pharmacological inhibition strategies targeting ACSS2. Molecular mechanism and mitophagy assessment were revealed by cleavage under target and tagmentation sequencing, RNA sequencing, bioinformatic analyses, transmission electron microscopy and JC-1 staining.
Results Our study revealed a distinct metabolic signature of HBV-related HCC, marked by elevated acetyl-CoA, which was driven by ACSS2. ACSS2 was upregulated by the carbohydrate response element-binding protein in HBV-related HCC. Furthermore, ACSS2 improved tumor cell proliferation, an effect that was dependent on its enzymatic activity. Mechanistically, ACSS2-induced acetyl-CoA accumulation activated voltage-dependent anion channels 1 transcription through increased H3K27ac occupancy, which subsequently promoted mitophagy and HBV-related HCC tumorigenesis. Notably, targeting ACSS2 by depletion or inhibition with a catalytic inhibitor significantly suppressed tumor growth.
Conclusions These findings not only illustrate the interplay between metabolic reprogramming, epigenetic modification, and tumorigenesis in the context of HBV infection, but also highlight ACSS2 as a novel metabolic vulnerability in HBV-related HCC. Therefore, targeting ACSS2 could be a novel strategy against HBV-related HCC.
Citations
Citations to this article as recorded by
From metabolites to chromatin: ACSS2-driven acetyl-CoA fuels H3K27ac chromatin remodeling in HBV-associated HCC: Editorial on “Acetyl-coenzyme A synthetase 2-mediated acetyl-coenzyme A accumulation promotes mitophagy and tumor growth via increased H3K27ac Hyeong-Jin Cho, Sung-Gyoo Park Clinical and Molecular Hepatology.2026; 32(3): 1444. CrossRef
Metabolic Reprogramming at the Tumor–Immune Interface in Hepatocellular Carcinoma Weiming Zhao, Ping Li Cells.2026; 15(15): 1357. CrossRef
Crosstalk between mitophagy and metabolism in cancer: Mechanisms and therapeutic opportunities Jingyi Cheng, Ting Xiao, Zhangui Tang, Yuhan Chen Free Radical Biology and Medicine.2026; 255: 573. CrossRef
Metabolic-epigenetic regulation of the HBV cccDNA reservoir: pathways underpinning viral persistence Qing Peng, Liyuan Hao, Shenghao Li, Fei Yu, Na Li, Fanghang Ye, Xiaoyu Hu Frontiers in Microbiology.2026;[Epub] CrossRef
Background/Aims Information about the association of glucagon-like peptide-1 receptor (GLP-1RA) with liver and non-liver complications is insufficient in patients with type 2 diabetes (T2D) and metabolic dysfunction-associated steatotic liver disease (MASLD). We conducted a target trial emulation study to evaluate whether GLP-1RA decreases the risk of liver and non-liver outcomes.
Methods Patients with T2D and MASLD initiating GLP-1RA or dipeptidyl peptidase-4 inhibitor (DPP-4i) were included from 2013 to 2022 in Merative™ Marketscan® Research Databases. Primary outcomes included incidences of (1) hepatocellular carcinoma (HCC) and cirrhosis, and (2) cardiovascular disease (CVD), chronic kidney disease (CKD), and non-liver cancer. Inverse probability of treatment weighting was applied to balance baseline characteristics and Cox regression models were conducted to estimate hazard ratio (HR) and 95% confidence interval (CI).
Results In the intention-to-treat design, GLP-1RA, compared with DPP-4i, had a significantly lower incidence (per 1,000 person-years) of HCC (0.8 vs. 1.7; HR 0.53, 95% CI 0.39–0.71), of cirrhosis (29.3 vs. 32.9; HR 0.91, 95% CI 0.86–0.96), of CVD (57.2 vs. 73.9; HR 0.90, 95% CI 0.86–0.95), of CKD (4.5 vs. 6.8; HR 0.73, 95% CI 0.64–0.84), and of non-liver cancer (16.9 vs. 22.9; HR 0.82, 95% CI 0.77–0.89). In the per-protocol design, significant inverse associations for these study outcomes still were observed, with HR 0.60–0.77.
Conclusions In this emulated target trial of nationwide patients with T2D and MASLD, GLP-1RA use, when compared with DPP-4i, was associated with a significantly lower risk of liver and non-liver complications.
Citations
Citations to this article as recorded by
Tirzepatide versus SGLT2 inhibitors for MASLD: a multi-institutional propensity score-matched cohort study Jheng-Yan Wu, Yu-Min Lin, Wan-Hsuan Hsu, Ting-Hui Liu, Ya-Wen Tsai, Po-Yu Huang, Min-Hsiang Chuang, Tsung Yu, Chih-Cheng Lai Hepatology International.2026; 20(2): 292. CrossRef
Impact of newer antihyperglycemic agents on hepatic complications: A systematic review and meta-analysis of data from 5.3 million patients with type 2 diabetes mellitus Jiwon Yang, Yeongseok Hwang, Jin-Sung Ju, Seungbong Han, Jihyun An, Ju Hyun Shim Hepatology.2026; 84(3): 851. CrossRef
Association of Semaglutide Treatment With Liver Cirrhosis and Hepatocellular Carcinoma in Type 2 Diabetes: A Population‐Based Cohort Study Assaf Issachar, Talish Razi, Ilya Borochov, Hadar Duskin Bitan, Ronen Arbel Diabetes, Obesity and Metabolism.2026; 28(7): 5704. CrossRef
Early cancer risk reduction after GLP-1RA use: Signal or bias?: Letter to the editor on “Glucagon-like peptide 1 receptor agonist and reduced liver and non-liver complications in adults with type 2 diabetes and metabolic dysfunction-associated steatotic l Shio-Shin Jean, Chih-Cheng Lai Clinical and Molecular Hepatology.2026; 32(2): e163. CrossRef
Letter to the editor on “Glucagon-like peptide 1 receptor agonist and reduced liver and non-liver complications in adults with type 2 diabetes and metabolic dysfunction-associated steatotic liver disease: a target trial emulation study” Chunyan Wang, Xu Han, Yinyan Li Clinical and Molecular Hepatology.2026; 32(2): e167. CrossRef
Correspondence to letter to the editor 1 on “Glucagon-like peptide 1 receptor agonist and reduced liver and non-liver complications in adults with type 2 diabetes and metabolic dysfunction-associated steatotic liver disease: a target trial emulation study Xianhua Mao, Mindie H. Nguyen Clinical and Molecular Hepatology.2026; 32(2): e231. CrossRef
Correspondence to letter to the editor 2 on “Glucagon-like peptide 1 receptor agonist and reduced liver and non-liver complications in adults with type 2 diabetes and metabolic dysfunction-associated steatotic liver disease: a target trial emulation study Xianhua Mao, Mindie H. Nguyen Clinical and Molecular Hepatology.2026; 32(2): e249. CrossRef
Letter to the editor on “Glucagon-like peptide 1 receptor agonist and reduced liver and non-liver complications in adults with type 2 diabetes and metabolic dysfunction-associated steatotic liver disease: a target trial emulation study” Xingyu Yao Clinical and Molecular Hepatology.2026; 32(2): e165. CrossRef
Correspondence to editorial on “Glucagon-like peptide 1 receptor agonist and reduced liver and non-liver complications in adults with type 2 diabetes and metabolic dysfunction-associated steatotic liver disease: a target trial emulation study” Xianhua Mao, Mindie H. Nguyen Clinical and Molecular Hepatology.2026; 32(2): e219. CrossRef
Reply to correspondence on “Glucagon-like peptide 1 receptor agonist and reduced liver and non-liver complications in adults with type 2 diabetes and metabolic dysfunction-associated steatotic liver disease: a target trial emulation study” Xingyu Yao Clinical and Molecular Hepatology.2026; 32(2): e267. CrossRef
GLP-1RA may open a new era for MASLD treatment: Editorial on “Glucagon-like peptide 1 receptor agonist and reduced liver and non-liver complications in adults with type 2 diabetes and metabolic dysfunction-associated steatotic liver disease: a target tria Ye Feng, Chengfu Xu Clinical and Molecular Hepatology.2026; 32(2): 924. CrossRef
Metabolic Dysfunction‐Associated Steatotic Liver Disease and Obesity: Pathogenesis, Diagnostics, Risk Stratification, and Therapeutic Approach Beom Kyung Kim The Kaohsiung Journal of Medical Sciences.2026;[Epub] CrossRef
Secular Trend in Glycaemic Management in Type 2 Diabetes Patients With and Without Cirrhosis Between 2000 and 2023: A Territory‐Wide Cohort Study Mary Yue Wang, Sherlot Juan Song, Nana Peng, Grace Lai‐Hung Wong, Vincent Wai‐Sun Wong, Jimmy Che‐To Lai, Terry Cheuk‐Fung Yip Alimentary Pharmacology & Therapeutics.2026; 64(3): 356. CrossRef
GLP-1 receptor agonist–SGLT-2 inhibitor combination and risk of major adverse liver and cardiovascular outcomes in adults with MASLD and type 2 diabetes Xianhua Mao, Hong Fan, Man-Fung Yuen, Ramsey Cheung, Wai-Kay Seto, Mindie H. Nguyen Hepatology.2026;[Epub] CrossRef
Tumor microenvironment and metabolic reprogramming in MASLD-related hepatocellular carcinoma Vanilla X. Zhang, Tiffany C.-Y. Yu, Yu M. Tsui, Irene O.-L. Ng Trends in Molecular Medicine.2026;[Epub] CrossRef
Hepatic Events Prevention by Antihyperglycemic Therapies and Intervention Comparisons in Type 2 Diabetes: The HEPATIC-T2DM Network Meta-analysis Pedro Robson Costa Passos, Rodrigo Motta, Valbert Oliveira Costa Filho, Mariana Macambira Noronha, Roberto Cavalcante Venâncio, Guilherme Grossi Lopes Cançado, Amanda Adler, Jeremy F. Cobbold, Jeremy W. Tomlinson Diabetes Care.2026; 49(6): 1144. CrossRef
Predictors of Discordance Between Controlled Attenuation Parameter and Magnetic Resonance-Proton Density Fat Fraction in Hepatic Steatosis Dong Yun Kim, Hyung-Jin Rhee, Beom Kyung Kim Clinical and Translational Gastroenterology.2026; 17(7): e01042. CrossRef
Glucagon-Like Peptide-1 Receptor Agonist Use and Liver-Related Outcomes in Metabolic Dysfunction-Associated Steatotic Liver Disease and Type 2 Diabetes in the All of Us Research Program Erik Almazan, Jonggi Choi, Tushar Kamath, Vy H. Nguyen, Eric Przybyszewski, Jiunn Song, Allison Carroll, Megan Michta, Tracey G. Simon, Raymond T. Chung American Journal of Gastroenterology.2026;[Epub] CrossRef
Association between hemoglobin glycation index and new-onset diabetes mellitus in individuals with chronic liver disease: Findings from a prospective cohort study using CHARLS data Yanyan Mao, Hui Kong, Li Wang, Fangyan Liao, Xiangwen Li Medicine.2026; 105(27): e49567. CrossRef
Glucagon-like peptide-1 receptor agonists versus dipeptidyl peptidase-4 inhibitors after liver resection for hepatocellular carcinoma in patients with type 2 diabetes: a target trial emulation study Yan-Jun Xiang, Zong-Han Liu, Jin-Kai Feng, Ying-Yi Qin, Hong-Ming Yu, Yu-Qiang Cheng, Gang Chen, Jia-Yi Wu, Yong-Yi Zeng, Yu-Fu Tang, Jian-Hua Rao, Feng-Min Zhang, Shi-Ye Yang, Gui-Ran Wang, Lin-Sen Ye, Ren Lang, Jian-Hua Lin, Yi-Tao Zheng, Ye-Fan Mao, Ho Gut.2026; : gutjnl-2026-338462. CrossRef
How Negative Controls Are Used in Pharmacoepidemiology: A Methodological Scoping Review of Real‐World Observational Studies of Glucagon‐Like Peptide‐1 Receptor Agonists Zhengxuan Li, Yinan Huang, Hua Chen, Jieni Li Pharmacoepidemiology and Drug Safety.2026;[Epub] CrossRef
Cancer outcomes and biological mechanisms among patients with type 2 diabetes mellitus using glucagon-like peptide-1 receptor agonists: a systematic review and meta-analysis Ejike Daniel Eze, Leopold Ntakirutimana, Swase Dominic Terkimbi, Muluken Walle, Abdullahi Hussein Umar, Diresibachew Haile Wondimu, Makinde Vincent Olubiyi, Onyinye Cynthia Okeke, Olufunke Onaadepo, Jimoh Abdulazeez, David Chibuike Ikwuka, Elemi John Ani, Frontiers in Oncology.2026;[Epub] CrossRef
GLP-1 receptor agonists at the crossroads of diabetes, hepatic steatosis, and hepatocellular carcinoma Alfredo Vozza, Filippo Biagi, Chiara Raggi, Francesco Vizzutti, Fabio Marra Internal and Emergency Medicine.2026;[Epub] CrossRef
Comparative risk of hepatocellular carcinoma and mortality among initiators of GLP-1 receptor agonists versus other glucose-lowering therapies: a target trial emulation Jesus Gibran Hernández-Pérez, Omer Abdelgadir, Subin Jang, Deepali K. Ernest, Xiaotao Zhang, Dimpy Shah, Arthur S. Hong, Jaime P. Almandoz, Lindsay G. Cowell, Sarah E. Messiah, David S. Lopez Hepatology International.2026;[Epub] CrossRef
Gestational Diabetes and Postpartum Cardiovascular, Kidney, and Metabolic Disorders Lili Liu, Junjie Anderson Lu, Esther E. Velasquez, Cande V. Ananth, Mindie H. Nguyen, Michelle A. Williams JAMA Network Open.2026; 9(8): e2628578. CrossRef
Associations Between Glucagon-Like Peptide-1 Receptor Agonists (GLP-1RAs) and Cancer Risk: A Systematic Review and Meta-Analysis Isha Lalani, Reynaldo Nambayan, Chantelle Carbonell, Yibing Ruan, Dylan E. O’Sullivan, Igor Stukalin, Robert J. Hilsden, Darren R. Brenner Cancer Control.2026;[Epub] CrossRef
Associations between glucagon-like peptide-1 receptor agonists and respiratory outcomes in chronic obstructive pulmonary disease and diabetes Kuang-Ming Liao, Ya-Wen Tsai, Konstantinos Kostikas, Gerard J Criner, Jheng-Yan Wu, Chih-Cheng Lai QJM: An International Journal of Medicine.2026;[Epub] CrossRef
Evaluating causal protective effect of dual GLP-1R/GIPR agonists on MASLD: A Mendelian randomization and colocalization study Yangke Cai, Siyuan Xie, Liyi Xu, Jiamin Chen, Jianting Cai European Journal of Pharmacology.2025; 1005: 178088. CrossRef
Impaired Thyroid Hormone Sensitivity is Associated with Increased
Risk of Liver Fibrosis in Euthyroid Population: A Cross-Sectional Analysis of
NHANES Xingyu Yao, Kaiwen Xiao, Hein Ko Oo Hormone and Metabolic Research.2025; 57(09): 511. CrossRef
Background/Aims With the obesity pandemic, metabolic dysfunction-associated steatotic liver disease (MASLD) is the most common liver disease and a leading cause of end-stage liver disease and liver-related deaths in the USA. Therefore, we aimed to compare the long-term outcomes of patients with MASLD and cirrhosis with and without bariatric surgery.
Methods Patients were retrospectively identified from the California Department of Healthcare Access and Information database, 2005 to 2019, for a population-based cohort study. Propensity score matching (PSM) was used to balance background risks between patients with cirrhosis who underwent bariatric surgery and those who did not. Overall, liver-related and non-liver-related mortality were analyzed.
Results Of 91,708 eligible patients with MASLD and cirrhosis, PSM yielded 2,107 patients who underwent bariatric surgery and 8,428 non-bariatric controls. Compared to matched controls, patients who underwent bariatric surgery had lower 5-year overall (24.9% vs. 37.1%; p<0.0001), liver-related (3.3% vs. 14%; p<0.0001), and non-liver-related mortality (22.3% vs. 26.9%; p=0.046). In multivariable analysis, bariatric surgery was associated with decreased overall mortality (adjusted hazard ratio [aHR]=0.63; p<0.0001), liver-related (aHR=0.24; p<0.0001), and non-liverrelated (aHR=0.81; p=0.0026) mortality. However, only laparoscopic surgeries were associated with lower overall mortality (aHR=0.39; p<0.0001) whereas open surgeries were associated with higher overall mortality (aHR=1.24; p=0.022).
Conclusions Patients with MASLD and cirrhosis who underwent bariatric surgery, specifically laparoscopic approaches, had significantly lower mortality risk than non-surgical counterparts.
Citations
Citations to this article as recorded by
Arginase 1 promotes hepatic lipogenesis by regulating ERK2/PPARγ signaling in a non-canonical manner Mingyang Shao, Xiaoyue Cao, Yuwei Chen, Ziqi Zhu, Yuke Shu, Qing Tao, Qing Xu, Tingting Ma, Zhenru Wu, Menglin Chen, Yongjie Zhou, Rong Yao, Junhua Gong, Jiayin Yang, Yujun Shi Nature Communications.2026;[Epub] CrossRef
Ultrasound-derived Fat Fraction for Pre-operative Prediction and Monitoring of Hepatic Steatosis Normalization After Metabolic Surgery in Patients With Obesity Die Hu, HuaWu Yang, GeMei Yu, Li Wei, Ying Liu, Hong Zhou, WeiWen Cai, Hong Wen, Guo Li, Shuang Wu, Yang Zhou Ultrasound in Medicine & Biology.2026; 52(6): 1062. CrossRef
Research Progress on the Recompensation of Liver Cirrhosis 源 高 Advances in Clinical Medicine.2026; 16(03): 2709. CrossRef
Metabolic and Bariatric Surgery: The Contraindications of the Past are the Indications of the Future Tala Abedalqader, Joseph Klim, Tony Boutros, Nour El Ghazal, Juan Ignacio Isaac, Andrew G. Robertson, Mohammad Kermansaravi, Omar M. Ghanem Current Obesity Reports.2026;[Epub] CrossRef
Discordant FIB-4 and liver stiffness in metabolic dysfunction-associated steatotic liver disease: Toward clinically coherent risk stratification: Letter to the Editor on “Histological severity and hepatic outcomes in patients with metabolic dysfunction-as Zhanna Zhang, Zichen Yu, Gongqiang Wu Clinical and Molecular Hepatology.2026; 32(3): e297. CrossRef
Alcohol-Related Liver Disease After Metabolic Bariatric Surgery: Reassessing the Hidden Risk—A Meta-Analysis Chenglou Zhu, Wenhan Liu Obesity Surgery.2026; 36(9): 5011. CrossRef
Differential Characteristics and Survival Outcomes of Patients With Cirrhosis According to Underlying Liver Aetiology Yu Shi, Nicholas Chien, Ashley Fong, Vy H. Nguyen, Surya Teja Gudapati, Angela Chau, Sally Tran, Linda Henry, Ramsey Cheung, Changqing Zhao, Minjuan Jin, Mindie H. Nguyen Alimentary Pharmacology & Therapeutics.2025; 61(10): 1622. CrossRef
A leap in the dark: Bariatric surgery for treatment of metabolic dysfunction-associated steatotic liver disease related cirrhosis: Editorial on “Bariatric surgery reduces long-term mortality in patients with metabolic dysfunction-associated steatotic live Jing Zeng, Jian-Gao Fan Clinical and Molecular Hepatology.2025; 31(2): 610. CrossRef
Letter to the editor on “Bariatric surgery reduces long-term mortality in patients with metabolic dysfunction-associated steatotic liver disease and cirrhosis” Wei Wang, Yating Xie, Ailei Xu Clinical and Molecular Hepatology.2025; 31(2): e143. CrossRef
Advancing precision medicine in metabolic dysfunction-associated steatotic liver disease Bryan A. Priego-Parra, Rocío Gallego-Durán, Berenice M. Román-Calleja, José Antonio Velarde-Ruiz Velasco, Manuel Romero-Gómez, Jordi Gracia-Sancho Trends in Endocrinology & Metabolism.2025; 36(11): 1000. CrossRef
Correspondence to editorial on “Bariatric surgery reduces long-term mortality in patients with metabolic dysfunction-associated steatotic liver disease and cirrhosis” Nicholas A. Rouillard, Linda Henry, Mindie H. Nguyen Clinical and Molecular Hepatology.2025; 31(2): e173. CrossRef
Reply to correspondence on “Bariatric surgery reduces long-term mortality in patients with metabolic dysfunction-associated steatotic liver disease and cirrhosis” Jing Zeng, Jian-Gao Fan Clinical and Molecular Hepatology.2025; 31(2): e218. CrossRef
Letter to the editor on “Bariatric surgery reduces long-term mortality in patients with metabolic dysfunction-associated steatotic liver disease and cirrhosis” Weixiong Zhu, Xuefan Zeng, Zengxi Yang, Yusheng Cheng, Wence Zhou Clinical and Molecular Hepatology.2025; 31(3): e252. CrossRef
Association between body roundness index and risks of all-cause and cardiovascular mortality in adults with metabolic dysfunction-associated steatotic liver disease: NHANES 1999–2018 Yanshan Yi, Li Yang Frontiers in Nutrition.2025;[Epub] CrossRef
Letter to the editor on “Bariatric surgery reduces long-term mortality in patients with metabolic dysfunction-associated steatotic liver disease and cirrhosis” Chi-Kuei Hsu, Po-Yu Huang, Chih-Cheng Lai Clinical and Molecular Hepatology.2025; 31(3): e247. CrossRef
Efficacy and Safety of Bariatric Surgery in Well-Compensated Liver Cirrhosis: A Systematic Review and a Single-Arm Meta-analysis Pandora Fonseca, Leonardo Pereira, João Gabriel Braga, Giovanna Macanhã Scremin, Luísa de Araujo, Julia Alves, Gabriel de França, Pedro Bregion, Rafael Rego, Maria Farias, Victor Ivano Obesity Surgery.2025; 35(10): 4246. CrossRef
Metabolic Dysfunction Associated to Steatotic Liver Disease: A Review Janna Vanessa Diaz Torres, Vanessa Rocío Villanueva Guerrero, Jennifer Patricia Vargas Gómez, Fredy Javier Pacheco Miranda, Lorena Rocío Orozco Álvarez, Joseph David León Insignares, Marian Mares, Héctor Mario Rodríguez Ortiz, Evelyn Mendoza-Torres Metabolic Syndrome and Related Disorders.2025; 23(10): 427. CrossRef
Endoscopic Bariatric Therapies for Metabolic Dysfunction-Associated Steatotic Liver Disease: Mechanistic Insights and Metabolic Implications Wissam Ghusn, Mira Sridharan, Rachel Fromer, Muhammet Ozdemir, Madeleine G. Haff, Eric J. Vargas Biomedicines.2025; 13(10): 2437. CrossRef
Huapeng Lin, Grace Lai-Hung Wong, Xinrong Zhang, Terry Cheuk-Fung Yip, Ken Liu, Yee Kit Tse, Vicki Wing-Ki Hui, Jimmy Che-To Lai, Henry Lik-Yuen Chan, Vincent Wai-Sun Wong
Clin Mol Hepatol 2022;28(1):77-90. Published online November 5, 2021
Background/Aims We aimed to determine the association between blood urea level and incident cirrhosis, hepatic decompensation, and hepatocellular carcinoma in chronic liver disease (CLD) patients.
Methods The association between blood urea level and liver fibrosis/liver-related events were evaluated on continuous scale with restricted cubic spline curves based on generalized additive model or Cox proportional hazards models. Then, the above associations were evaluated by urea level within intervals.
Results Among 4,282 patients who had undergone liver stiffness measurement (LSM) by transient elastography, baseline urea level had a U-shaped association with LSM and hepatic decompensation development after a median follow-up of 5.5 years. Compared to patients with urea of 3.6–9.9 mmol/L, those with urea ≤3.5 mmol/L (adjusted hazard ratio [aHR], 4.15; 95% confidence interval [CI], 1.68–10.24) and ≥10 mmol/L (aHR, 5.22; 95% CI, 1.86–14.67) had higher risk of hepatic decompensation. Patients with urea ≤3.5 mmol/L also had higher risk of incident cirrhosis (aHR, 3.24; 95% CI, 1.50–6.98). The association between low urea level and incident cirrhosis and hepatic decompensation was consistently observed in subgroups by age, gender, albumin level, and comorbidities. The U-shaped relationship between urea level and LSM was validated in another population screening study (n=917). Likewise, urea ≤3.5 mmol/L was associated with a higher risk of incident cirrhosis in a territory-wide cohort of 12,476 patients with nonalcoholic fatty liver disease at a median follow-up of 9.9 years (aHR, 1.27; 95% CI, 1.03–1.57).
Conclusions We identified a U-shaped relationship between the urea level and liver fibrosis/incident cirrhosis/hepatic decompensation in patients with CLD.
Citations
Citations to this article as recorded by
An RFH-NPT-based nomogram for predicting the long-term survival of liver cirrhosis patients: a multicenter study Chengbin Zhu, Yuchao Wu, Fulian Zhao, Ruojing Wang, Qijuan Zang, Zhe Jiao, Yage Zhu, Taotao Yan, Juan Du, Li Zhu, Weimin Li, Yongqin Li, Qing Fan, Anping Wu, Xiaodan Liu, Dianzu Liu, Xianmei Tang, Xiaoxiao Xu, Huaying Liao, Yu Li, Yingren Zhao, Yingli He, European Journal of Clinical Nutrition.2026; 80(1): 87. CrossRef
Advances in Electrochemical Urea Biosensors: Trends and Future Prospects Samar Shurbaji, Arshad Khan, Mohammad K. Hassan, Amine Bermak, Wen‐Di Li, Kabir H Biswas, Bo Wang Advanced Sensor Research.2026;[Epub] CrossRef
A dual-purpose paper-based electrochemical device for enzyme-free sensing of urinary urea and micro-powering applications: towards self-powered electrochemical sensors Madhuvallika Sreekonda, Sohel Samad Chaus, Sweta Lal Microchemical Journal.2026; 225: 118076. CrossRef
Spontaneous Recovery and Mortality in Patients With ALD Referred for Early Liver Transplantation Bima J. Hasjim, Allison J. Kwong, Amanda Cheung, Katherine M. Cooper, Deepika Devuni, Kawthar Mohamed, Giovanni Roldan, Kevin Wang, Sasha Deutsch-Link, Hersh Shroff, Kaleb Tesfai, Veeral Ajmera, Nicholas Lim American Journal of Gastroenterology.2026;[Epub] CrossRef
Hepatic Cysts in Korea: Prevalence, Incidence, and Risk Factors Based on a 5.8-Year Follow-up Health Screening Cohort Kang Seo, Yujeong Kim, Sang Hyuk Park, Nam-Joon Yi, Jeong Hee Yoon, Goh Eun Chung, Jeong-Moo Lee, Seoung Yoon Rho, Min Su Park, Eun Kyung Choe, Aesun Shin Journal of Korean Medical Science.2026;[Epub] CrossRef
Molecularly Imprinted Polymer-Based Electrochemical Sensor for Detection of Urea as a Potential Clinical Biomarker Nihal Ermiş Journal of the Turkish Chemical Society Section A: Chemistry.2026; 2026(2): 1. CrossRef
Preclinical studies on the antitumor and non‐toxic effect of combining pirfenidone with vinorelbine and carboplatin in non‐small cell lung cancer Helena Branco, Catarina A. Rodrigues, Júlio Oliveira, Nuno Mendes, Catarina Antunes, Irina Amorim, Lúcio L. Santos, M. Helena Vasconcelos, Cristina P. R. Xavier International Journal of Cancer.2025; 156(9): 1756. CrossRef
Phase-dependent hepatotoxicity of Aluminum oxide nanoparticles mediated through the intestinal microbiota Mingshu Li, Fuchang Deng, Li Dong, Xiaona Wang, Haiyan Jiang, Siyu Yao, Yuanyuan Chen, Lian Duan, Huamao Du, Guangqiu Qin, Song Tang Environment International.2025; 198: 109398. CrossRef
Parenclitic network mapping predicts survival in critically ill patients with sepsis Emily Ito, Tope Oyelade, Matthew Wikner, Jinyuan Liu, Watjana Lilaonitkul, Ali R. Mani Physiological Reports.2025;[Epub] CrossRef
The role of urea in pathological conditions O.B. Kvasnytska, A.I. Gozhenko, D.D. Ivanov, O.O. Popadynets KIDNEYS.2025; 14(3): 251. CrossRef
Colchicine induces developmental defects and renal toxicity in zebrafish by upregulating the oxidative stress Fang Chen, Haiyan Wei, Dalong Liao, Yong Huang, Yijian Chen, Huiqiang Lu, Rong Xu Comparative Biochemistry and Physiology Part C: Toxicology & Pharmacology.2025; 298: 110328. CrossRef
Neurological alterations in adult female rats developmentally exposed to a glyphosate-based herbicide: Potential role of the immune system Cristina Eugenia Gallegos, Mariana Bartos, Fernanda Gumilar, Diego Nicolás Nabaes Jodar, Ileana Lencinas, Cristina Bras, Betina Noemí García, Jorge Andrés Delbés, Sergio Dominguez, Carlos Javier Baier Toxicology.2025; 518: 154279. CrossRef
Inverse Association Between METS-IR and Lung Cancer Risk: The Role of BMI in a Nationwide Korean Cohort Bo-Kyung Shine, In Hwa Jeong, Minkook Son, Bongjo Kim, Sang Yi Moon, Jong Yoon Lee, Hye Ryeon Kim, Seok Jae Huh Cancers.2025; 17(23): 3727. CrossRef
ULTRASONOGRAPHIC INDICATORS OF THE KIDNEYS IN COMBINED LIVER AND KIDNEY PATHOLOGY IN DOGS V. Rudyashko Scientific and Technical Bulletin оf State Scientific Research Control Institute of Veterinary Medical Products and Fodder Additives аnd Institute of Animal Biology.2025; 26(2): 216. CrossRef
Cross-sectional and longitudinal associations between fatty liver index and kidney function using updated MASLD and CKD–EPI 2021 definitions: a population-based study with region-specific cutoffs Sina Bazmi, Mohammadreza Fardaei, Reza Homayounfar, Maryam Kazemi, Babak Pezeshki, Reza Malekzadeh, Nasrollah Ghahramani, Mojtaba Farjam European Journal of Medical Research.2025;[Epub] CrossRef
Comparison of Engineered Liver 3D Models and the Role of Oxygenation for Patient‐Derived Tumor Cells and Immortalized Cell Lines Cocultured with Tumor Stroma in the Detection of Hepatotoxins Mona Mansouri, Astha Lamichhane, Dola Das, Federico Aucejo, Hossein Tavana, Nic D. Leipzig Advanced Biology.2024;[Epub] CrossRef
The Role and Limitations of the Reference Interval Within Clinical Chemistry and Its Reliability for Disease Detection Nathan E. Timbrell British Journal of Biomedical Science.2024;[Epub] CrossRef
The Role of Interleukin-6 and Procalcitonin in Kidney Patients have Bacterial and Viral Infection Anwar Aiad Gaber, Jawad Kadhum Muraih Biomedical and Pharmacology Journal.2024; 17(1): 461. CrossRef
Investigation of the effects of Theranekron and Sorafenib treatments on carcinogenesis, apoptosis and biochemical profile in hepatocellular carcinoma in rats Serdar Vanli, Firuze Kurtoglu, Beyza S. Alan, Gokhan Akcakavak, Ozgur Ozdemir Toxicology Mechanisms and Methods.2024; 34(7): 750. CrossRef
Association of blood urea nitrogen with all-cause and cardiovascular mortality in hyperlipidemia: NHANES 1999–2018 Jing Shen, Zhen Wang, Yong Liu, Tao Wang, Xiao-Yu Wang, Xin-Hui Qu, Zhi-Ping Chen, Xiao-Jian Han Lipids in Health and Disease.2024;[Epub] CrossRef
Association between serum vitamin D status and severity of liver cirrhosis: implications for therapeutic targeting in Nigerian patients Winnifred Njideka Adiri, Bruno Basil, Chinwe Philomena Onyia, Promise Asogwa, Oluchi Joy Ugwuanyi, Olive Obienu, Uchenna Nkemdilim Ijoma, Slyvester Chuks Nwokediuko BMC Gastroenterology.2024;[Epub] CrossRef
Age and the relative importance of liver‐related deaths in nonalcoholic fatty liver disease Huapeng Lin, Terry Cheuk‐Fung Yip, Xinrong Zhang, Guanlin Li, Yee‐Kit Tse, Vicki Wing‐Ki Hui, Lilian Yan Liang, Jimmy Che‐To Lai, Stephen Lam Chan, Henry Lik‐Yuen Chan, Grace Lai‐Hung Wong, Vincent Wai‐Sun Wong Hepatology.2023; 77(2): 573. CrossRef
Trends in risk factor control and treatment among patients with non‐alcoholic fatty liver disease and type 2 diabetes between 2000 and 2020: A territory‐wide study Xinrong Zhang, Terry Cheuk‐Fung Yip, Yee‐Kit Tse, Vicki Wing‐Ki Hui, Guanlin Li, Huapeng Lin, Lilian Yan Liang, Jimmy Che‐To Lai, Mandy Sze‐Man Lai, Johnny T. K. Cheung, Henry Lik‐Yuen Chan, Stephen Lam Chan, Alice Pik‐Shan Kong, Grace Lai‐Hung Wong, Vinc Alimentary Pharmacology & Therapeutics.2023; 57(10): 1103. CrossRef
Effects of the in-utero dicyclohexyl phthalate and di-n-hexyl phthalate administration on the oxidative stress-induced histopathological changes in the rat liver tissue correlated with serum biochemistry and hematological parameters Duygu Aydemir, Mufide Aydogan-Ahbab, Nurhayat Barlas, Nuriye Nuray Ulusu Frontiers in Endocrinology.2023;[Epub] CrossRef
A comparative multi-level toxicity assessment of carbon-based Gd-free dots and Gd-doped nanohybrids from coffee waste: hematology, biochemistry, histopathology and neurobiology study Halyna Kuznietsova, Natalia Dziubenko, Konstantin Paliienko, Natalia Pozdnyakova, Natalia Krisanova, Artem Pastukhov, Tetiana Lysenko, Marina Dudarenko, Valeriy Skryshevsky, Vladimir Lysenko, Tatiana Borisova Scientific Reports.2023;[Epub] CrossRef
Alcohol consumption and the risk of liver disease: a nationwide, population-based study Sang Yi Moon, Minkook Son, Yeo Wool Kang, Myeongseok Koh, Jong Yoon Lee, Yang Hyun Baek Frontiers in Medicine.2023;[Epub] CrossRef
Effects of 4G mobile phone radiation exposure on reproductive, hepatic, renal, and hematological parameters of male Wistar rat Rohit Gautam, Sonali Pardhiya, Jay Prakash Nirala, Priyanka Sarsaiya, Paulraj Rajamani Environmental Science and Pollution Research.2023; 31(3): 4384. CrossRef
Is lean non-alcoholic fatty liver disease a distinct entity? Huapeng Lin, Vincent Wai-Sun Wong Hepatology International.2022; 16(2): 254. CrossRef
Reply to: Blood urea better than creatinine in prognosticating post‐TIPS outcomes: Hope or hype? Luisa Fürschuß, Florian Rainer, Angela Horvath, Vanessa Stadlbauer Liver International.2022; 42(7): 1702. CrossRef
Blood urea better than creatinine in prognosticating post‐TIPS outcomes: Hope or hype? Suprabhat Giri, Shivaraj Afzalpurkar, Sunil Kasturi, Dhiraj Agrawal Liver International.2022; 42(7): 1700. CrossRef
Screening and prediction of nonalcoholic fatty liver disease using a peripheral insulin resistance index: Potential benefits and limitations Soon Sun Kim, Jae Youn Cheong Clinical and Molecular Hepatology.2022; 28(4): 802. CrossRef
Nonalcoholic fatty liver disease (NAFLD) is currently the most common chronic liver disease worldwide. Although it has become one of the leading causes of cirrhosis and hepatocellular carcinoma in the Western world, the proportion of NAFLD patients developing these complications is rather small. Therefore, current guidelines recommend noninvasive tests for the initial assessment of NAFLD. Among the available non-invasive tests, transient elastography by FibroScan® (Echosens, Paris, France) is commonly used by hepatologists in Europe and Asia, and the machine has been introduced to the United States in 2013 with rapid adoption. Transient elastography measures liver stiffness and the controlled attenuation parameter simultaneously and can serve as a one-stop examination for both liver steatosis and fibrosis. Liver stiffness measurement also correlates with clinical outcomes and can be used to select patients for varices screening. Although obesity is a common reason for measurement failures, the development of the XL probe allows successful measurements in the majority of obese patients. This article reviews the performance and limitations of transient elastography in NAFLD and highlights its clinical applications. We also discuss the reliability criteria for transient elastography examination and factors associated with false-positive liver stiffness measurements.
Citations
Citations to this article as recorded by
Correlation of Lipid Profile, LFT, AST/ALT Ratio, BARD, FIB-4, NFS Score, TyG Index with Transient Elastography to Detect Better Noninvasive Marker in Overweight and Obese Patient in Tertiary Care Center, West Bengal: A Cross-Sectional Observational Study Ashis Kumar Saha, Puja Mahato, Aritra Kumar Ray, Ipshita Chatterjee, Moyukh Mukherjee International Journal of Health Sciences and Research.2026; : 314. CrossRef
Investigating confounding factors in shear wave speed measurements of fibrotic liver tissues: a computer simulation study Emily J. Miller, Yongmei M. Jin, Jingfeng Jiang Physical and Engineering Sciences in Medicine.2026; 49(2): 959. CrossRef
Metabolic liver imaging: What you need to know Luigi Asmundo, Amirkasra Mojtahed, Samay Prakash, Theodore T. Pierce, Jingwei Wei, Angelo Vanzulli Digestive and Liver Disease.2026; 58(4): 433. CrossRef
The Association Between Genetic Polymorphism in the Receptor for Advanced Glycation End-Products and Metabolic Dysfunction-Associated Steatotic Liver Disease Nourhan Mohammed, Mona M. Hassouna, Mohammed S. Mostafa, Amany E. Elashkar, Eman Abdelsameea, Mary A. Naguib Journal of Clinical and Experimental Hepatology.2026; 16(3): 103530. CrossRef
Risk Stratification of a Novel Noninvasive Fibrosis Score in Metabolic Dysfunction-Associated Steatotic Liver Disease Johnny T.K. Cheung, Xinrong Zhang, Grace Lai-Hung Wong, Terry Cheuk-Fung Yip, Huapeng Lin, Guanlin Li, Howard Ho-Wai Leung, Jimmy Che-To Lai, Sanjiv Mahadeva, Nik Raihan Nik Mustapha, Xiao-Dong Wang, Wen-Yue Liu, Wah-Kheong Chan, Ming-Hua Zheng, Vincent W Clinical Gastroenterology and Hepatology.2026; 24(10): 2732. CrossRef
The Usefulness of Metformin and Ganwei for Metabolic Dysfunction-Associated Steatotic Liver Disease: A Randomized, Placebo-Controlled Trial Chih-Lin Lin, Wei-You Li, Shang-Jung Wu, Patricia M. T. Chen, Allan Y. Chen, Cathy Shen-Jang Fann, Yi-Ming Arthur Chen International Journal of Molecular Sciences.2026; 27(5): 2411. CrossRef
Diagnostic performance of ultrasound-derived fat fraction for grading hepatic steatosis in patients with chronic liver diseases: a multicenter study Jiahao Han, Lixin Yang, Licheng Chu, Kexin Lou, Qun Zhang, Pingping Wang, Huiming Shen, Jia Li, Zuowei Bao European Radiology.2026; 36(9): 7047. CrossRef
Head‐to‐Head Comparison of Four Ultrasound Elastography Techniques in Detecting Advanced Fibrosis Jiahao Han, Lichen Chu, Lixin Yang, Kexin Lou, Guangbin Dou, Huiming Shen, Xiaojun Cheng, Zuowei Bao, Jia Li Portal Hypertension & Cirrhosis.2026; 5(3): 214. CrossRef
Liver steatosis and cognitive performance in aging: A pilot cross-sectional study Mohammad Khalafi, Seyed Hani Hojjati, Xiuyuan Hugh Wang, Emily B. Tanzi, Vanessa Liao, Sonal Kumar, Neal S. Parikh, Gloria C. Chiang Clinical Imaging.2026; 138: 110903. CrossRef
Multifocal fatty sparing areas in a steatotic liver mimicking hepatic lesions: a case report and review of the literature Hala Qasrawi, Tasneem Dweikat, Inam Hindi, Omar Issam Shakhshir, Abdallah S. Alem, Ali Shakhshir, Isra’ A. Salahat, Jihad Hamaida Journal of Medical Case Reports.2026;[Epub] CrossRef
Machine learning-based identification of targeted metabolomic biomarkers for early diagnosis and fibrosis-stage discrimination in metabolic dysfunction-associated steatotic liver disease Shimaa Abdelsattar, Hiba S. Al-Amodi, Hala F. M. Kamel, Mahmoud Nazih, Arwa Fadel Flemban, Sabry M. Abdelmegeed, Naglaa Abdelmawgoud Ahmed, Ehab Darwish, Ayman Ahmed Sakr, Yousef M. Abdelgawad, Basma M. Abdelgawad, Inas Moaz, Elaf Abozeid, Hanan M. Bedair Frontiers in Nutrition.2026;[Epub] CrossRef
Clinical characteristics of metabolic dysfunction-associated steatotic liver disease and its association with significant liver fibrosis in hospitalized patients with chronic hepatitis B: a single-center retrospective cross-sectional study Chun-Xia Wang, Jun Kang, Jia-Wei Zhang, Xiao-Yan Yuan, Dong Wang, Mao-Quan Li, Da-Feng Liu BMC Gastroenterology.2026;[Epub] CrossRef
Th17/Treg imbalance and clinical characteristics in psoriasis patients with metabolic dysfunction-associated steatotic liver disease: a cross-sectional analysis Sai Dong, Zixuan Qiu, Zheng Zhao, Hui Bao, Xiaoyang Liu, Zhanglei Mu, Jianzhong Zhang, Houmin Li, Bo Feng, Lin Cai Frontiers in Immunology.2026;[Epub] CrossRef
EASL-EASD-EASO guidance on the use of resmetirom and semaglutide as MASH-targeted therapy Frank Tacke, Paul Horn, Vincent Wai-Sun Wong, Vlad Ratziu, Elisabetta Bugianesi, Sven Francque, Shira Zelber-Sagi, Cyrielle Caussy, Michael Roden, Amalia Gastaldelli, Andreea Ciudin, Barbara McGowan Journal of Hepatology.2026;[Epub] CrossRef
Natural disease course of chronic visceral acid sphingomyelinase deficiency in adults: A first step toward treatment criteria Eline C. B. Eskes, Laura van Dussen, Marion M. M. G. Brands, Frédéric M. Vaz, Johannes M. F. G. Aerts, André B. P. van Kuilenburg, Barbara Sjouke, Carla E. M. Hollak Journal of Inherited Metabolic Disease.2025;[Epub] CrossRef
Risk Stratification of Patients with Metabolic Dysfunction-associated Steatotic Liver Disease: Steatohepatitis, Fibrosis, and Hepatocellular Carcinoma Mohamed El-Kassas, Heba A. Othman, Mohamed Elbadry, Khalid Alswat, Yusuf Yilmaz Journal of Clinical and Experimental Hepatology.2025; 15(1): 102415. CrossRef
The Loge GDR Was Strongly Associated with NAFLD as a Predictor in Normoalbuminuric Patients with Type 2 Diabetes Baolan Ji, Guanqi Gao, Hongyan Zhao, Jie Sheng, Xuan Ma, Shuwei Shi, Bo Ban Diabetes, Metabolic Syndrome and Obesity.2025; Volume 18: 115. CrossRef
Diagnostic Accuracy of Non-Invasive Diagnostic Tests for Nonalcoholic Fatty Liver Disease: A Systematic Review and Network Meta-Analysis Yuxin Sun, Die Hu, Mingkun Yu, Shi-Bing Liang, Youyou Zheng, Xin Wang, Guangdong Tong Clinical Epidemiology.2025; Volume 17: 53. CrossRef
Development of a Fatty Liver Index Based on Real‐World Data Wenfeng Ding, Lanlan Liu, Wenjing Lu, Yingli Li, Jing Zhang, Cui Zhang, Yufei Wang, Xueping Ma, Xiaoli Yang iLABMED.2025; 3(1): 33. CrossRef
Machine Learning–Based Biomarker Identification for Early Diagnosis of Metabolic Dysfunction–Associated Steatotic Liver Disease Jolie Boullion, Amanda Husein, Akshat Agrawal, Diensn Xing, Md Ismail Hossain, Md Shenuarin Bhuiyan, Oren Rom, Steven A Conrad, John A Vanchiere, A Wayne Orr, Christopher G Kevil, Mohammad Alfrad Nobel Bhuiyan The Journal of Clinical Endocrinology & Metabolism.2025; 110(11): e3866. CrossRef
Estimated sdLDL-C as a biomarker of hepatic steatosis severity in MASLD: a retrospective study Shuo Jiang, Fan Zhang, Hui Yang, Xue Han, Jieru Mao, Guojun Zheng, Yan Fan BMC Gastroenterology.2025;[Epub] CrossRef
The value of MR spectroscopy and MR elastography in assessing hepatic involvement of chronic visceral acid sphingomyelinase deficiency in adults Eline C.B. Eskes, Sandra A.M. van den Berg-Faaij, Nienke P.M. Wassenaar, Carla E.M. Hollak, Aart J. Nederveen, Barbara Sjouke Molecular Genetics and Metabolism.2025; 145(2): 109107. CrossRef
The new definition of metabolic dysfunction-associated steatotic liver disease: the role of ultrasound and elastography Xinrui Jin, Terry Cheuk-Fung Yip, Grace Lai-Hung Wong, Vincent Wai-Sun Wong, Jimmy Che-To Lai Ultrasonography.2025; 44(3): 189. CrossRef
Prospective Comparison of 2D-Shear Wave Elastography and Vibration-Controlled Transient Elastography in Assessing Liver Fibrosis in Metabolic Dysfunction-Associated Steatotic Liver Disease Qingxin Li, Yanhang Gao, Dongxuan Wang, Xiaoxue Zhu, Jing Jia, Lili Liu, Huining Tian, Lishuang Wang, Yingwen Zhang, Dezhi Zhang Academic Radiology.2025; 32(9): 5100. CrossRef
Hepatic fibrosis in morbidly obese patients: fibroscan accuracy Maged Tharwat Elghannam, Moataz Hassan Hassanien, Ahmed Aly ELRay, Hoda Mohamed Abu-Taleb, Yosry Abdelrahman Ameen, Gamal Mohammed ELattar, Emad Abdelwahab Turky, Mohammed Darwish ELTalkawy Exploration of Digestive Diseases.2025;[Epub] CrossRef
Role of liver transient elastography in detecting cirrhosis with esophageal and gastric varices and evaluating variceal severity Chaozhi Wang BMC Gastroenterology.2025;[Epub] CrossRef
Attenuation Based Quantitative Evaluation of Hepatic Steatosis Using US: Current Status and Future Perspective Dong Ho Lee Journal of the Korean Society of Radiology.2025; 86(3): 321. CrossRef
Perturbation solution for second-harmonic generation in focused shear wave beams in soft solids Philip G. Kaufinger, John M. Cormack, Kyle S. Spratt, Mark F. Hamilton Wave Motion.2025; 139: 103595. CrossRef
Prevalence of Hepatic Steatosis and Fibrosis in Asian Indian Individuals with Type 2 Diabetes Khandhulwa Chandramouli Bhuvanesswar, Brijendra Kumar Srivastava, Anandakumar Amutha, Varun Damle, Aswin Krishna, Prasanna Kumar Gupta, Phillips Routray, Dhanasekaran Killivalavan, Saravanan Jebarani, Ulagamathesan Venkatesan, Rosette James Chakkalakal, Diabetes Therapy.2025; 16(9): 1797. CrossRef
Circulating microRNAs as potential non-invasive biomarkers for diagnosis and severity assessment of Metabolic Dysfunction-Associated Steatotic Liver Disease: a case–control study Hanan M Nafeh, Nourhan M Abbas, Mohamed A El-Mokhtar, Hebatallah M. Hassan, Sahar M Hassany The Egyptian Journal of Internal Medicine.2025;[Epub] CrossRef
Impact of genotyping (PTPN2, rs2542151) and (MBOAT7, rs641738) in prediction of fibrosis in Metabolic dysfunction- associated steatotic liver disease’ patients Shimaa Abdelsattar, Hiba S. Al-Amodi, Hala F. M. Kamel, Zeinab A. Kasemy, Ehab Darwish, Asmaa Mosbeh, Ayman A. Sakr, Hanaa M. Elgazzar, Mervat Abdelkareem, Mai Abozeid, Shimaa K. Zewain, Hanan M. Bedair, Sabry M. Abdelmageed Frontiers in Endocrinology.2025;[Epub] CrossRef
Long-Term Feasibility and Outcomes of a Digital Health Program to Improve Liver Fat and Cardiometabolic Markers in Individuals With Nonalcoholic Fatty Liver Disease: Prospective Single-Arm Feasibility Study Sigridur Björnsdottir, Hildigunnur Ulfsdottir, Elias Freyr Gudmundsson, Bartosz Dobies, Kolbrun Sveinsdottir, Ari Pall Isberg, Gudlaug E A Magnusdottir, Thrudur Gunnarsdottir, Tekla Karlsdottir, Gudlaug Bjornsdottir, Sigurdur Sigurdsson, Saemundur Oddsson JMIR Cardio.2025; 9: e72074. CrossRef
DC09, Derivative of 3‐(2‐hydroxy‐5‐methoxyphenyl)‐1‐(5‐methylfuran‐2‐yl)prop‐2‐en‐1‐one Attenuates Nonalcoholic Fatty Liver Disease by Targeting PI3K/Akt Pathway: Insights From In‐Vivo Zebrafish Model and In‐Vitro HepG2 Cell Santhanam Sanjai Dharshan, B. Haridevamuthu, Karthikeyan Ramamurthy, B. Aswinanand, Dhivya Loganathan Sumathi, Ilavenil Soundharrajan, Mansour K. Gatasheh, S. Karthick Raja Namasivayam, Kathiravan Muthu Kumaradoss, Jesu Arockiaraj Journal of Biochemical and Molecular Toxicology.2025;[Epub] CrossRef
Current Update on Nomenclature, Diagnosis, and Management of Metabolic Dysfunction–associated Steatotic Liver Disease: Radiologists’ Perspective Eri G. Osta, Florentino Saenz Rios, Sriram Jaganathan, Courtney Thomas, Eugenia Tsai, Venkateswar Surabhi, Srinivasa R. Prasad, Venkata S. Katabathina RadioGraphics.2025;[Epub] CrossRef
Hepatic steatosis/fibrosis related biomarkers in patients with metabolic dysfunction-associated steatotic liver disease Zhi Peng, Zijin Wang, Juan Wang, Xuefeng Li Biomarkers in Medicine.2025; 19(23): 1239. CrossRef
Fibrotic Burden in Patients With Hepatitis B Virus–Related Cirrhosis Is Independently Associated With Poorer Kidney Outcomes Chan-Young Jung, Hui-Yun Jung, Hyung Woo Kim, Geun Woo Ryu, Jung Il Lee, Sang Hoon Ahn, Seung Up Kim, Beom Seok Kim The Journal of Infectious Diseases.2024; 229(1): 108. CrossRef
User Engagement, Acceptability, and Clinical Markers in a Digital Health Program for Nonalcoholic Fatty Liver Disease: Prospective, Single-Arm Feasibility Study Sigridur Björnsdottir, Hildigunnur Ulfsdottir, Elias Freyr Gudmundsson, Kolbrun Sveinsdottir, Ari Pall Isberg, Bartosz Dobies, Gudlaug Erla Akerlie Magnusdottir, Thrudur Gunnarsdottir, Tekla Karlsdottir, Gudlaug Bjornsdottir, Sigurdur Sigurdsson, Saemundu JMIR Cardio.2024; 8: e52576. CrossRef
Focused Shear Wave Beam Propagation in Tissue-Mimicking Phantoms John M. Cormack, Yu-hsuan Chao, Branch T. Archer, Kang Kim, Kyle S. Spratt, Mark F. Hamilton IEEE Transactions on Biomedical Engineering.2024; 71(2): 621. CrossRef
Development of Cost-Effective Fatty Liver Disease Prediction Models in a Chinese Population: Statistical and Machine Learning Approaches Liang Zhang, Yueqing Huang, Min Huang, Chun-Hua Zhao, Yan-Jun Zhang, Yi Wang JMIR Formative Research.2024; 8: e53654. CrossRef
Exploring the link: magnesium intake and hepatic steatosis in Americans Xingxing Chen, Liying Fu, Zhongxin Zhu, Yunchao Wang Frontiers in Nutrition.2024;[Epub] CrossRef
The associations between fibrosis changes and liver‐related events in patients with metabolic dysfunction‐associated steatotic liver disease Hye Won Lee, Kun Hee Kim, Sang Hoon Ahn, Han Chu Lee, Jonggi Choi Liver International.2024; 44(6): 1448. CrossRef
A Prospective Randomised Comparative Four-arm Intervention Study of Efficacy and Safety of Saroglitazar and Vitamin E in Patients With Non-alcoholic Fatty Liver Disease (NAFLD)/Non-alcoholic Steatohepatitis (NASH)-SVIN TRIAL Bilal A. Mir, Brij Sharma, Rajesh Sharma, Vishal Bodh, Ashish Chauhan, Tahir Majeed, Inaamul Haq, Neetu Sharma, Dikshant Sharma Journal of Clinical and Experimental Hepatology.2024; 14(5): 101398. CrossRef
Comparative value of controlled attenuation (CAPc) and continuous controlled attenuation (CAP) parameters for different stages of non-alcoholic fatty liver disease A. A. Goncharov, A. N. Sasunova, V. A. Isakov Experimental and Clinical Gastroenterology.2024; (2): 55. CrossRef
Exploring the association between dietary fiber intake and hepatic steatosis: insights from NHANES Xingxing Chen, Liying Fu, Zhongxin Zhu, Yunchao Wang BMC Gastroenterology.2024;[Epub] CrossRef
Appendicular Skeletal Muscle Mass to Visceral Fat Area Ratio Predicts Hepatic Morbidities Eugene Han, Yong-ho Lee, Sang Hoon Ahn, Bong-Soo Cha, Seung Up Kim, Byung-Wan Lee Gut and Liver.2024; 18(3): 509. CrossRef
Associations between allostatic load and hepatic steatosis and liver fibrosis: evidence from NHANES 2017–2020 Zhikun Dai, Xiaohui Zhou BMC Public Health.2024;[Epub] CrossRef
NAFLD (MASLD)/NASH (MASH): Does It Bother to Label at All? A Comprehensive Narrative Review Consolato M. Sergi International Journal of Molecular Sciences.2024; 25(15): 8462. CrossRef
Agile 3+ and Agile 4 scores predict chronic kidney disease development in metabolic dysfunction‐associated steatotic liver disease Chan‐Young Jung, Jung Il Lee, Sang Hoon Ahn, Seung Up Kim, Beom Seok Kim Alimentary Pharmacology & Therapeutics.2024; 60(8): 1051. CrossRef
Electrical and Viscoelastic Parameters of Erythrocytes as a Part of Diagnostic Models for Differentiating Fatty Liver Disease of Mixed Genesis from Non-Alcoholic and Alcohol-Related Fatty Liver Disease M. V. Kruchinina, M. F. Osipenko, M. V. Parulikova, A. A. Gromov Russian Journal of Gastroenterology, Hepatology, Coloproctology.2024; 34(3): 38. CrossRef
Diagnostic models for differentiating fatty liver disease of alcohol and non-alcoholic genesis M. V. Kruchinina, M. F. Osipenko, M. V. Parulikova, A. V. Belkovets, E. V. Kruchinina Meditsinskiy sovet = Medical Council.2024; (15): 80. CrossRef
Metabolic dysfunction-associated steatotic liver disease: The question of long-term high-normal alanine aminotransferase as a screening test Terence N Moyana World Journal of Gastroenterology.2024; 30(42): 4576. CrossRef
Liver fibrosis as a barometer of systemic health by gauging the risk of extrahepatic disease Amedeo Lonardo, Stefano Ballestri, Gyorgy Baffy, Ralf Weiskirchen Metabolism and Target Organ Damage.2024;[Epub] CrossRef
Prevalence of Liver Steatosis Among Workers in Ouagadougou and Associated Factors: A Cross‐Sectional Study Delphine Napon‐Zongo, Jeoffray Diendere, Armel M. Sanou, Abou Coulibaly, Abdoulaye Dera, Nina G. M. Ouattara, Augustin N. Zeba, Seni Kouanda JGH Open.2024;[Epub] CrossRef
Metabolic dysfunction-associated fatty liver disease: bridging cardiology and hepatology Xiao-Dong Zhou, Giovanni Targher, Christopher D. Byrne, Michael D. Shapiro, Li-Li Chen, Ming-Hua Zheng Cardiology Plus.2024; 9(4): 275. CrossRef
Жирные кислоты мембран эритроцитов как биомаркеры неалкогольной жировой болезни печени у мужчин М. В. Кручинина, М. В. Паруликова, Н. Е. Першина, Э. В. Кручинина Ateroscleroz.2023; 18(4): 362. CrossRef
Prevalence of at-risk NASH and its association with metabolic syndrome in US adults with NAFLD, 2017–2018 Julia Y. Payne, Naim Alkhouri, Phuc Le, Michael B. Rothberg, Prido Polanco, Celine Sakkal, Srinivasan Dasarathy Hepatology Communications.2023; 7(1): e0019. CrossRef
Metabolic Profile Reflects Stages of Fibrosis in Patients with Non-Alcoholic Fatty Liver Disease Nila Jambulingam, Roberta Forlano, Benjamin Preston, Benjamin H. Mullish, Greta Portone, Yama Baheer, Michael Yee, Robert D. Goldin, Mark R. Thursz, Pinelopi Manousou International Journal of Molecular Sciences.2023; 24(4): 3563. CrossRef
Special Population Ajay Duseja, Arka De, Vincent Wong Clinics in Liver Disease.2023; 27(2): 451. CrossRef
How many times should we repeat measurements of the ultrasound-guided attenuation parameter for evaluating hepatic steatosis? Duck Min Seo, Sang Min Lee, Ji Won Park, Min-Jeong Kim, Hong Il Ha, Sun-Young Park, Kwanseop Lee Ultrasonography.2023; 42(2): 227. CrossRef
Noninvasive risk assessment of hepatic decompensation in patients with hepatitis B virus‐related liver cirrhosis David Sooik Kim, Beom Kyung Kim, Jae Seung Lee, Hye Won Lee, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Nikolaos Pyrsopoulos, Seung Up Kim Journal of Gastroenterology and Hepatology.2023; 38(8): 1372. CrossRef
Effect of fish oil supplementation on the concentration of miRNA-122, FGF-21 and liver fibrosis in patients with NAFLD: Study protocol for a randomized, double-blind and placebo-controlled clinical trial Lygia N. Barroso, Jessica Salarini, Nathalie Carvalho Leite, Cristiane A. Villela-Nogueira, Alberto Dávalos, Maria das Graças Tavares Carmo, Wilza Arantes Ferreira Peres Clinical Nutrition ESPEN.2023; 57: 117. CrossRef
B-mode shear wave elastography can be an alternative method to vibration-controlled transient elastography according to a moderate-scale population study Masashi Hirooka, Yohei Koizumi, Yoshiko Nakamura, Ryo Yano, Kana Hirooka, Makoto Morita, Yusuke Imai, Yoshio Tokumoto, Masanori Abe, Yoichi Hiasa Journal of Medical Ultrasonics.2023; 50(4): 473. CrossRef
Advanced liver fibrosis predicts heart failure and hospitalizations in people with type 2 diabetes: A prospective cohort study from Hong Kong Diabetes Register Alice Pik-Shan Kong, Eric Siu-Him Lau, Chun-Kwan O, Andrea On-Yan Luk, Terry Cheuk-Fung Yip, Elaine Yee-Kwan Chow, Raymond Kwok, Hye Won Lee, Grace Lai-Hung Wong, Ronald Ching-Wan Ma, Henry Lik-Yuen Chan, Vincent Wai-Sun Wong, Juliana Chung-Ngor Chan Diabetes Research and Clinical Practice.2023; 202: 110825. CrossRef
Clinical impact of hepatic steatosis on chronic hepatitis B patients in Asia: A systematic review and meta‐analysis Run Zhou, Luping Yang, Binbin Zhang, Yunpeng Gu, Tingting Kong, Wei Zhang, Lei Sun, Chunlan Liu, Ningjia Kong, Jie Li, Junping Shi Journal of Viral Hepatitis.2023; 30(10): 793. CrossRef
Analysis of clinical features and identification of risk factors in patients with non-alcoholic fatty liver disease based on FibroTouch Yan Liao, Lei Liu, Jiayao Yang, Xiaoli Zhou, Xiaoli Teng, Yixi Li, Ying Wan, Jian Yang, Zhaohong Shi Scientific Reports.2023;[Epub] CrossRef
MAFLD fibrosis score: Using routine measures to identify advanced fibrosis in metabolic‐associated fatty liver disease Johnny T. K. Cheung, Xinrong Zhang, Grace Lai‐Hung Wong, Terry Cheuk‐Fung Yip, Huapeng Lin, Guanlin Li, Howard Ho‐Wai Leung, Jimmy Che‐To Lai, Sanjiv Mahadeva, Nik Raihan Nik Mustapha, Xiao‐Dong Wang, Wen‐Yue Liu, Vincent Wai‐Sun Wong, Wah‐Kheong Chan, Mi Alimentary Pharmacology & Therapeutics.2023; 58(11-12): 1194. CrossRef
Use of a controlled attenuation parameter for the diagnosis of non-alcoholic fatty liver disease Alexey A. Goncharov, Armida N. Sasunova, Vladimir I. Pilipenko, Vasily A. Isakov Terapevticheskii arkhiv.2023; 95(8): 641. CrossRef
Duration of type 2 diabetes and liver-related events in nonalcoholic fatty liver disease: A landmark analysis Xinrong Zhang, Terry Cheuk-Fung Yip, Yee-Kit Tse, Vicki Wing-Ki Hui, Guanlin Li, Huapeng Lin, Lilian Yan Liang, Jimmy Che-To Lai, Henry Lik-Yuen Chan, Stephen Lam Chan, Alice Pik-Shan Kong, Grace Lai-Hung Wong, Vincent Wai-Sun Wong Hepatology.2023; 78(6): 1816. CrossRef
Low Relative Handgrip Strength Is Associated with a High Risk of Non-Alcoholic Fatty Liver Disease in Italian Adults: A Retrospective Cohort Study Samantha Maurotti, Roberta Pujia, Elisa Mazza, Maria Francesca Pileggi, Franco Arturi, Maria Grazia Tarsitano, Tiziana Montalcini, Arturo Pujia, Yvelise Ferro Applied Sciences.2023; 13(22): 12489. CrossRef
Non-Invasive Diagnostic of NAFLD in Type 2 Diabetes Mellitus and Risk Stratification: Strengths and Limitations Alina Boeriu, Daniela Dobru, Crina Fofiu Life.2023; 13(12): 2262. CrossRef
Non-alcoholic fatty liver disease in obese subjects as related to increasing insulin resistance and deteriorating glucose control: Three years of follow-up from a longitudinal survey Thomas Forst, Isabel Botz, Matthias Berse, Stephan Voswinkel, Mares-Elaine Strempler, Sybille Baumann, Maria Marinez Journal of Diabetes & Metabolic Disorders.2023; 23(1): 999. CrossRef
Noninvasive tests for liver fibrosis in 2024: are there different scales for different diseases? Jimmy Che-To Lai, Lilian Yan Liang, Grace Lai-Hung Wong Gastroenterology Report.2023;[Epub] CrossRef
Advanced liver fibrosis measured by transient elastography predicts chronic kidney disease development in individuals with non-alcoholic fatty liver disease Chan-Young Jung, Geun Woo Ryu, Hyung Woo Kim, Sang Hoon Ahn, Seung Up Kim, Beom Seok Kim Diabetologia.2022; 65(3): 518. CrossRef
Diagnostic Performance of 2-D Shear Wave Elastography on the Evaluation of Hepatic Fibrosis with Emphasis on Impact of the Different Region-of-Interest Methods Eun Mi Kim, Ji-Won Park, Sang Min Lee, Min-Jeong Kim, Hong Il Ha, Sung-Eun Kim, Eun Soo Kim, Young Chul Kim, Kwanseop Lee Ultrasound in Medicine & Biology.2022; 48(2): 198. CrossRef
Cross-talk between non-alcoholic fatty liver disease and cardiovascular disease: implications for future trial design Pierpaolo Pellicori, Muthiah Vaduganathan, João Pedro Ferreira, Faiez Zannad, Arun J. Sanyal Diabetes & Metabolism.2022; 48(2): 101281. CrossRef
Controlled attenuation parameter measured using transient elastography for the noninvasive assessment of macrovesicular steatosis in potential living liver donors Sunyoung Lee, Kyoung Won Kim, So Yeon Kim, Nieun Seo, Gi-Won Song, Sung-Gyu Lee Ultrasonography.2022; 41(1): 164. CrossRef
Transient Elastography–Assessed Hepatic Steatosis and Fibrosis Are Associated With Body Composition in the United States Aynur Unalp-Arida, Constance E. Ruhl Clinical Gastroenterology and Hepatology.2022; 20(4): e808. CrossRef
Non-invasive tests of non-alcoholic fatty liver disease Guanlin Li, Xinrong Zhang, Huapeng Lin, Lilian Yan Liang, Grace Lai-Hung Wong, Vincent Wai-Sun Wong Chinese Medical Journal.2022; 135(5): 532. CrossRef
Comparison of FibroScan-Aspartate Aminotransferase (FAST) Score and Other Non-invasive Surrogates in Predicting High-Risk Non-alcoholic Steatohepatitis Criteria Jae Seung Lee, Hye Won Lee, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Jae Young Jang, Soo Young Park, Hyun Woong Lee, Chun Kyon Lee, Seung Up Kim Frontiers in Medicine.2022;[Epub] CrossRef
Association Between Skeletal Muscle Mass and Severity of Steatosis and Fibrosis in Non-alcoholic Fatty Liver Disease Wen Guo, Xin Zhao, Mengyuan Miao, Xiuru Liang, Xiaona Li, Pei Qin, Jing Lu, Wenfang Zhu, Juan Wu, Chen Zhu, Nianzhen Xu, Qun Zhang Frontiers in Nutrition.2022;[Epub] CrossRef
Vibration-controlled Transient Elastography in NAFLD: Review Study Hasan Ozkan, Abdullah M Ozercan Euroasian Journal of Hepato-Gastroenterology.2022; 12(S1): S41. CrossRef
Magnetic resonance imaging improves stratification of fibrosis and steatosis in patients with chronic liver disease Han Ah Lee, Seung-seob Kim, Jin-Young Choi, Yeon Seok Seo, Beom Jin Park, Ki Choon Sim, Seung Up Kim Abdominal Radiology.2022; 47(11): 3733. CrossRef
DETERMINANTS OF SIGNIFICANT HEPATIC FIBROSIS IN TYPE 2 DIABETES PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE IN SOUTH INDIA. A V Ramya, P Thirumal INTERNATIONAL JOURNAL OF SCIENTIFIC RESEARCH.2022; : 24. CrossRef
Pulse-Echo Quantitative US Biomarkers for Liver Steatosis: Toward Technical Standardization David T. Fetzer, Ivan M. Rosado-Mendez, Michael Wang, Michelle L. Robbin, Arinc Ozturk, Keith A. Wear, Juvenal Ormachea, Timothy A. Stiles, J. Brian Fowlkes, Timothy J. Hall, Anthony E. Samir Radiology.2022; 305(2): 265. CrossRef
The triglyceride glucose-body mass index: a non-invasive index that identifies non-alcoholic fatty liver disease in the general Japanese population Haofei Hu, Yong Han, Changchun Cao, Yongcheng He Journal of Translational Medicine.2022;[Epub] CrossRef
Myocyte Enhancer Factor 2A Contributes to the TGF-β1-Mediated Cholangiocyte Epithelial to Mesenchymal Transition and Senescence in Cholestatic Liver Fibrosis Guangxi Zhou, Fei Hou, Heng He, Yuan Xue, Yibo Wang, Xueying Chen, Fengqin Zhu Frontiers in Bioscience-Landmark.2022;[Epub] CrossRef
Clinical Feasibility of Quantitative Ultrasound Imaging for Suspected Hepatic Steatosis: Intra- and Inter-examiner Reliability and Correlation with Controlled Attenuation Parameter Sun Kyung Jeon, Jeong Min Lee, Ijin Joo Ultrasound in Medicine & Biology.2021; 47(3): 438. CrossRef
Updates in the quantitative assessment of liver fibrosis for nonalcoholic fatty liver disease: Histological perspective Gwyneth Soon, Aileen Wee Clinical and Molecular Hepatology.2021; 27(1): 44. CrossRef
Noninvasive evaluation of liver fibrosis: comparison of the stretched exponential diffusion-weighted model to other diffusion-weighted MRI models and transient elastography Jae Hyon Park, Nieun Seo, Yong Eun Chung, Seung Up Kim, Yung Nyun Park, Jin-Young Choi, Mi-Suk Park, Myeong-Jin Kim European Radiology.2021; 31(7): 4813. CrossRef
Screening for undiagnosed non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH): A population-based risk factor assessment using vibration controlled transient elastography (VCTE) Wayne Eskridge, John M. Vierling, Wayne Gosbee, Gabriella A. Wan, May-Linh Hyunh, Henry E. Chang, Daisuke Tokuhara PLOS ONE.2021; 16(11): e0260320. CrossRef
A prospective 5-year study on the use of transient elastography to monitor the improvement of non-alcoholic fatty liver disease following bariatric surgery Shirley Yuk-Wah Liu, Vincent Wai-Sun Wong, Simon Kin-Hung Wong, Grace Lai-Hung Wong, Carol Man-sze Lai, Candice Chuen-Hing Lam, Sally She-Ting Shu, Henry Lik-Yuen Chan, Enders Kwok-Wai Ng Scientific Reports.2021;[Epub] CrossRef
Ultrasound Elastography in Liver Tissue: Current Status Zhang, MD Mingzhu, Ding, MD Zhaoyan, Niu, MD Xiaoyan, Gao, MD Yuxiu, Zhao, MD Cheng ADVANCED ULTRASOUND IN DIAGNOSIS AND THERAPY.2021; 5(3): 197. CrossRef
Magnetic Resonance Spectroscopy of Hepatic Fat from Fundamental to Clinical Applications Duanghathai Pasanta, Khin Thandar Htun, Jie Pan, Montree Tungjai, Siriprapa Kaewjaeng, Hongjoo Kim, Jakrapong Kaewkhao, Suchart Kothan Diagnostics.2021; 11(5): 842. CrossRef
Current and Emerging Biomarkers and Imaging Modalities for Nonalcoholic Fatty Liver Disease: Clinical and Research Applications T. Hydes, E. Brown, A. Hamid, A.C. Bateman, D.J. Cuthbertson Clinical Therapeutics.2021; 43(9): 1505. CrossRef
Non-alcoholic fatty liver disease in adults: clinic, diagnostics, treatment. Guidelines for therapists, third version L. B. Lazebnik, E. V. Golovanova, S. V. Turkina, K. L. Raikhelson, S. V. Okovityy, O. M. Drapkina, I. V. Maev, A. I. Martynov, G. E. Roitberg, O. V. Khlynova, D. I. Abdulganieva, S. A. Alekseenko, M. D. Ardatskaya, I. G. Bakulin, N. V. Bakulina, A. O. Bue Experimental and Clinical Gastroenterology.2021; 1(1): 4. CrossRef
Detectability of Liver Steatosis and Fibrosis with Transient Elastography and Controlled Attenuation Parameter in Residents of St. Petersburg V. P. Kovyazina, K. L. Raikhelson, M. K. Prashnova, E. V. Pazenko, L. K. Palgova, E. A. Kondrashina Russian Journal of Gastroenterology, Hepatology, Coloproctology.2021; 31(1): 31. CrossRef
Liver Stiffness-Based Risk Prediction Model for Hepatocellular Carcinoma in Patients with Nonalcoholic Fatty Liver Disease Jae Seung Lee, Dong Hyun Sinn, Soo Young Park, Hye Jung Shin, Hye Won Lee, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Joo Hyun Oh, Jung Il Lee, Seung Up Kim Cancers.2021; 13(18): 4567. CrossRef
Diagnostic Performance of Noninvasive Methods for Liver Biopsy by Fibroscan in Pediatric Ghobad Heidari, Farzaneh Motamed, Bita Heirati, Parisa Rahmani Journal of Child Science.2021; 11(01): e55. CrossRef
The Need for Alternatives to Liver Biopsies: Non-Invasive Analytics and Diagnostics James Neuberger, Owen Cain Hepatic Medicine: Evidence and Research.2021; Volume 13: 59. CrossRef
Clinical relevance of dynamic risk assessment for developing hepatocellular carcinoma during prolonged antiviral therapy Han Ah Lee, Beom Kyung Kim, Seung Up Kim Journal of Hepatology.2020; 73(1): 222. CrossRef
A Survey of Liver Cancer Specialists’ Views on the National Liver Cancer Screening Program in Korea Won Sohn, Young-Sun Lee, Jae Geun Lee, Jihyun An, Eun Sun Jang, Dong Ho Lee, Dong Hyun Sinn Journal of Liver Cancer.2020; 20(1): 53. CrossRef
Confounding factors of non-invasive tests for nonalcoholic fatty liver disease Janae Wentong Wai, Charmaine Fu, Vincent Wai-Sun Wong Journal of Gastroenterology.2020; 55(8): 731. CrossRef
High body mass index hinders fibrosis improvement in patients receiving long‐term tenofovir therapy in hepatitis B virus‐related cirrhosis Young Eun Chon, Kyu Sik Jung, Yeonjung Ha, Mi Na Kim, Joo Ho Lee, Seong Gyu Hwang, Sang Hoon Ahn, Do Young Kim, Kwang‐Hyub Han, Jun Yong Park Journal of Viral Hepatitis.2020; 27(11): 1119. CrossRef
Application of Baveno Criteria and Modified Baveno Criteria with Shear-wave Elastography in Compensated Advanced Chronic Liver Disease Seong Hee Kang, Soon Koo Baik, Moon Young Kim Journal of Korean Medical Science.2020;[Epub] CrossRef
Hepatocellular Carcinoma and Non-Alcoholic Fatty Liver Disease: A Step Forward for Better Evaluation Using Ultrasound Elastography Monica Lupsor-Platon, Teodora Serban, Alexandra-Iulia Silion, Alexandru Tirpe, Mira Florea Cancers.2020; 12(10): 2778. CrossRef
Triantennary GalNAc Molecular Imaging Probes for Monitoring Hepatocyte Function in a Rat Model of Nonalcoholic Steatohepatitis Anurag Mishra, Tamara R. Castañeda, Erik Bader, Bettina Elshorst, Sheila Cummings, Petra Scherer, Dinesh S. Bangari, Claudia Loewe, Herman Schreuder, Christoph Pöverlein, Mike Helms, Seth Jones, Gernot Zech, Thomas Licher, Michael Wagner, Manfred Schudok, Advanced Science.2020;[Epub] CrossRef
Saroglitazar in patients with non-alcoholic fatty liver disease and diabetic dyslipidemia: a prospective, observational, real world study Omesh Goyal, Sahil Nohria, Prerna Goyal, Jaskirat Kaur, Sarit Sharma, Ajit Sood, Rajoo Singh Chhina Scientific Reports.2020;[Epub] CrossRef
Effects of Ademetionine on Liver Fibrosis, Level of Pentraxin-3 and Metabolic Indicators in Patients with Comorbid Course of Non-alcoholic Liver Disease and Arterial Hypertension T. N. Alexandrova, O. Ya. Babak Ukraïnsʹkij žurnal medicini, bìologìï ta sportu.2020; 5(6): 95. CrossRef
East Asia expert opinion on treatment initiation for chronic hepatitis B Jia‐Horng Kao, Tsung‐Hui Hu, Jidong Jia, Masayuki Kurosaki, Young‐Suk Lim, Han‐Chieh Lin, Dong Hyun Sinn, Yasuhito Tanaka, Vincent Wai‐Sun Wong, Man‐Fung Yuen Alimentary Pharmacology & Therapeutics.2020; 52(10): 1540. CrossRef
Advanced Liver Fibrosis Predicts Unfavorable Long-Term Prognosis in First-Ever Ischemic Stroke or Transient Ischemic Attack Minyoul Baik, Hyo Suk Nam, Ji Hoe Heo, Hyung Jong Park, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Kwang-Hyub Han, Hye Sun Lee, Seung Up Kim, Young Dae Kim Cerebrovascular Diseases.2020; 49(5): 474. CrossRef
First
Prev
